In Vitro Activity of a Novel Quinolone, UB-8902, Against Ofloxacin-Resistant Mycobacterium tuberculosis Isolates.

In Vitro Activity of a Novel Quinolone, UB-8902, Against Ofloxacin-Resistant Mycobacterium tuberculosis Isolates.

Publication date: Mar 10, 2020

The main objective of this study was to compare in vitro activities of a novel fluoroquinolone (FQ), UB-8902, with ofloxacin (OFX), levofloxacin (LFX), and moxifloxacin (MOX) against Mycobacterium tuberculosis isolates. Eleven OFX-resistant and 11 drug-susceptible clinical isolates were studied. Individual minimum inhibitory concentrations of OFX, LFX, MOX, and UB-8902 were determined using Middlebrook 7H11 agar. The concentrations studied ranged from 0.125 to 128??g/mL in twofold dilutions. UB-8902 was more active than LFX and similar to MOX for OFX-resistant M. tuberculosis isolates. In addition, UB-8902 and MOX showed equal activity against drug-susceptible isolates, both being more active than OFX and LFX. In conclusion, the new FQ, UB-8902, showed good activity against OFX-resistant isolates. Moreover, it showed better activity than OFX and LFX and was equivalent to MOX against FQ-susceptible clinical isolates. UB-8902 can be considered as a drug with potential antituberculous activity, similar to MOX.

Concepts Keywords
Fluoroquinolone Chemical compounds
Levofloxacin Drugs
LFX Fluoroquinolone antibiotics
MOX RTT
Moxifloxacin Organic compounds
Mycobacterium Tuberculosis Levofloxacin
Ofloxacin Moxifloxacin
Quinolone Mycobacterium
Tuberculosis

Semantics

Type Source Name
drug DRUGBANK Ofloxacin
drug DRUGBANK Levofloxacin
drug DRUGBANK Moxifloxacin
disease MESH tuberculosis
pathway KEGG Tuberculosis
drug DRUGBANK Aspartame
drug DRUGBANK Tropicamide

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *